After signing the informed consent, the participant will be allocated to either intervention or control group, then each participant will use either 0.15% benzydamine (Comparator) or 4% tulsi (Intervention) four times a day and also once half an hour before each radiotherapy session.
the primary outcome is the severity of oral mucositis will assess by Oral Mucositis Assessment Scale (OMAS) and secondary outcomes are pain will assess Numerical rating scale (NRS), Oral Assessment Guide (OAG), and Patient-Reported Oral Mucositis( PROMS scale) All outcomes will be recorded at baseline, and 8, 15 days
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
42
4% topical oral spray
0.15% topical oral spray
Severity of mucositis
Oral Mucositis Assessment Scale (OMAS)
Time frame: up to 15 days
Pain and burning sensation
assess by numerical rating scale (NRS) (10 points scale)
Time frame: up to 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.